SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.

Trial Profile

SPIRIT III: A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System (EECSS) in the Treatment of Subjects With de Novo Native Coronary Artery Lesions.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Everolimus (Primary) ; Paclitaxel
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms SPIRIT-III
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 11 Nov 2011 Four-year results presented at the 23rd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
    • 04 Nov 2011 Five-year results will be presented at the 23rd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics (TCT-2011), according to an Abbott media release.
    • 05 Apr 2011 Pooled analysis results presented at the 60th Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top